SCHEMBL5690083

SCHEMBL5690083

O=C(O)Cc1ccc(OC2CCN(C(=O)Oc3ccc(N4C(=O)C5CCCCC5C4=O)cn3)CC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
EPHX2 P34913 3/20 0.44
HRH1 P35367 1/20 0.40
CCR3 P51677 1/20 0.40
KCNH2 Q12809 1/20 0.40
ACACB O00763 5/20 0.39
LIPE Q05469 2/20 0.38
FFAR4 Q5NUL3 2/20 0.38
GPR119 Q8TDV5 1/20 0.37
ALDH1A1 P00352 2/20 0.37
LMNA P02545 1/20 0.37
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36
GPBAR1 Q8TDU6 1/20 0.36
ACACA Q13085 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5689609 0.90 KMT2A (0.47) KMT2AL3MBTL1ACACBLIPEGPR119
SCHEMBL5690596 0.88 SRD5A1 (0.45) KMT2AL3MBTL1EPHX2HRH1CCR3
SCHEMBL5691369 0.84 EPHX2 (0.41) EPHX2HRH1CCR3KCNH2ACACB
SCHEMBL5687360 0.83 LIPE (0.42) KMT2AL3MBTL1ACACBLIPEGPR119
SCHEMBL5688207 0.83 LIPE (0.42) KMT2AL3MBTL1EPHX2ACACBLIPE
SCHEMBL5904319 0.82 KMT2A (0.41) KMT2AL3MBTL1GPR119ALDH1A1LMNA
SCHEMBL5687328 0.79 KMT2A (0.42) KMT2AL3MBTL1LIPEGPR119ALDH1A1
SCHEMBL5688038 0.76 ALDH1A1 (0.38) KMT2AL3MBTL1LIPEGPR119ALDH1A1
SCHEMBL5687808 0.76 EPHX2 (0.43) KMT2AEPHX2ALDH1A1LMNAMAPT
SCHEMBL5690467 0.75 EPHX2 (0.49) KMT2AEPHX2LIPE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160851-A1 Substituted piperidine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636207-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111032-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160851-A1 Substituted piperidine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636207-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111032-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160851-A1 Substituted piperidine carbamates LIPE, PNLIP, LIPC KMT2A 1520/4885L3MBTL1 2710/4885EPHX2 3290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.